Growth & profitability
- Revenue has grown 10.0% per year over the past 5 years.
- Operating margin has contracted, at -343.6% in the latest year.
PTGX Financials Protagonist Therapeutics, Inc
12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $46M | -$130M | 0.0% | -343.6% | -21.2% | -19.5% | $56M | — | $128M |
| 2024 | $434M | $275M | 0.0% | 58.2% | 40.8% | 37.0% | $183M | — | $97M |
| 2023 | $60M | -$79M | 0.0% | -156.1% | -23.5% | -22.1% | -$71M | — | $187M |
| 2022 | $27M | -$127M | 0.0% | -494.2% | -59.1% | -51.4% | -$109M | — | $126M |
| 2021 | $27M | -$126M | 0.0% | -460.0% | -41.8% | -36.1% | -$109M | — | $124M |
| 2020 | $29M | -$66M | 0.0% | -225.4% | -23.7% | -20.4% | -$73M | — | $117M |
| 2019 | $231000 | -$77M | 0.0% | -34857.6% | -96.5% | -49.8% | -$42M | $10M | $33M |
| 2018 | $31M | -$39M | 0.0% | -136.7% | -34.6% | -27.9% | -$50M | — | $82M |
| 2017 | $20M | -$37M | 0.0% | -188.9% | -30.6% | -22.6% | $3M | — | $106M |
| 2016 | — | -$37M | — | — | -42.5% | -39.6% | -$30M | — | $21M |
| 2015 | — | -$15M | — | — | 54.2% | -100.1% | -$15M | — | $4M |
| 2014 | — | -$11M | — | — | 87.7% | — | — | — | $9M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $213M | $163M | 0.0% | 74.4% | 19.4% | 18.4% | $219M | — | $420M |
| Mar '26 | — | $4M | — | — | 0.6% | 0.5% | -$49M | — | $194M |
| Dec '25 | — | -$44M | — | — | -7.2% | -6.6% | -$37M | — | $128M |
| Sep '25 | — | -$39M | — | — | -6.1% | -5.6% | -$2M | — | $114M |
| Jun '25 | $6M | -$35M | 0.0% | -758.0% | -5.2% | -4.8% | -$30M | — | $169M |
| Mar '25 | — | -$12M | — | — | -1.7% | -1.6% | $125M | — | $140M |
| Dec '24 | — | $132M | — | — | 19.5% | 17.7% | -$29M | — | $97M |
| Sep '24 | — | -$33M | — | — | -6.2% | -5.5% | -$29M | — | $131M |
| Jun '24 | — | -$31M | — | — | -5.7% | -5.0% | $269M | — | $356M |
| Mar '24 | — | $207M | — | — | 37.0% | 32.9% | -$28M | — | $173M |
| Dec '23 | — | $27M | — | — | 8.1% | 7.6% | $17M | — | $187M |
| Sep '23 | — | -$34M | — | — | -11.3% | -10.3% | -$27M | — | $231M |
| Jun '23 | — | -$38M | — | — | -13.1% | -12.0% | -$26M | — | $235M |
| Mar '23 | — | -$34M | — | — | -15.6% | -14.1% | -$34M | — | $128M |
| Dec '22 | — | -$34M | — | — | -15.9% | -13.8% | -$32M | — | $126M |
| Sep '22 | — | -$31M | — | — | -12.8% | -11.1% | -$25M | — | $153M |
| Jun '22 | — | -$41M | — | — | -15.3% | -13.2% | -$14M | — | $120M |
| Mar '22 | — | -$21M | — | — | -6.9% | -6.0% | -$38M | — | $98M |
| Dec '21 | — | -$37M | — | — | -12.3% | -10.6% | -$27M | — | $124M |
| Sep '21 | — | -$34M | — | — | -10.3% | -9.1% | -$29M | — | $121M |
Valuation over time
How the market has priced PTGX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 9.1× (Dec '24) to 21.2× (Nov '25).
- The price-to-sales ratio has risen from 56.0× (Mar '23) to 209.2× (Sep '26).
P/E
P/S
Frequently asked questions
Is PTGX growing its revenue and profit?
Over the past 5 years, Protagonist Therapeutics, Inc's revenue has grown 10.0% per year. These are computed facts, not advice.
How much debt does PTGX have?
As of FY2025, Protagonist Therapeutics, Inc reported — of total debt against $128M of cash.
What is PTGX's profit margin?
In FY2025, gross margin was —, operating margin -343.6%, and net margin -282.8%.
What is PTGX's P/E ratio?
As of Sep '26, Protagonist Therapeutics, Inc traded at a price-to-earnings ratio of about 21.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.